SEC Form 4 · accession 0001193125-26-259557
Sight Sciences, Inc. · SGHT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Catherine Mazzacco
Director
Period of report
Jun 4, 2026
Accepted (ET)
Jun 5, 2026 · 4:09 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001531177
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 4, 2026 | A | 28,261 | $0.00 | A | 69,276 | D | |
| Common StockF3 | holding | — | — | — | 37,492 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.
- F2Includes (i) 30,952 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 10,063 RSUs granted to the Reporting Person on June 8, 2023 which are subject to vesting as previously reported.
- F3These shares of Common Stock are held of record by the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 (the "Trust"), of which the Reporting Person is beneficiary.